Research Shows Benefits of Drug Therapy for Diabetic Eye Disease

Research Shows Promising Early Evidence of the Superior Benefits of Drug Therapy for Diabetic Eye Disease

Contact:
Leslie Schwartz, National Director, Media Relations
Phone: 212-479-7553
E-mail: lschwartz@jdrf.org     

May 1, 2008, New York, NY – A JDRF collaboration between Johns Hopkins researchers and Genentech along with other researchers across the United States has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

These findings, representing the six-month primary end-point evaluation of the READ-2 clinical trial coordinated by the Johns Hopkins University, were presented Monday, April 28, at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology, in Fort Lauderdale, Florida. 

According to Barbara Araneo, Ph.D., director of the complications program at JDRF, “These are very encouraging results, showing that drugs we have been testing in human clinical trials can be effective in slowing or stopping the effects of eye disease brought on by diabetes.” Genentech is currently sponsoring two Phase 3 studies to test the clinical benefit of ranibizumab in diabetic macular edema. More information about these studies can be found at http://clinicaltrials.gov/ct2/show/NCT00473330?term=Genentech+and+macular+edema&rank=1; and http://clinicaltrials.gov/ct2/show/NCT00473382?term=Genentech+and+macular+edema&rank=2.

The investigator-initiated, multi-center READ-2 Study (Ranibizumab for Edema of the mAcula in Diabetes), which began in December 2006, was designed to test the long-term safety and effectiveness of injections of the drug ranibizumab in patients with diabetic macular edema, a condition characterized by swelling of the central portion of the retina, or macula, at the back of the eye. In addition, the trial sought to determine the comparative efficacy of ranibizumab versus conventional treatment — laser photocoagulation therapy — or both together.

Macular edema, one of the most common causes of blindness, occurs when fluid and protein deposits collect on or under the macula, causing it to thicken and swell.

Participating in the clinical trial were 126 diabetic patients (average age 62) with documented diabetic macular edema (DME) prior to enrollment; the majority had 20/80 vision in the eye that was treated. Patients were randomly assigned to receive one of three interventions: ranibizumab, laser photocoagulation, or a combination of the two treatments.  At each visit over the course of the six-month treatment period, patients were evaluated for vision, retinal thickening, and general eye health. Although the study ended at six months, patients will be monitored for two years.

Patients treated with ranibizumab experienced significantly greater improvements in visual acuity, or clarity of vision, compared with patients receiving either of the other interventions.  On average, the vision of ranibizumab-treated patients improved to 20/63 at month six, compared with essentially unchanged acuity scores of 20/80+2 in both the laser and the combination treatment groups.

In addition, patients treated with ranibizumab had a 56 percent reduction in excess retinal thickness, whereas only an 11 percent reduction was seen in those receiving laser treatments. 

The READ-2 study, which was funded as part of JDRF’s research addressing the complications of type 1 diabetes, is also supported by Johns Hopkins and the pharmaceutical company Genentech. It builds on the results of the READ-1 Study, a Phase 1 trial that was also a collaboration with John Hopkins researchers and Genentech. This first trial established the ability of ranibizumab to reduce edema and improve visual acuity in patients with diabetic macular edema. The READ-2 study is taking place at 14 clinical centers around the United States, including at the Although the study is no longer recruiting patients, additional study information can be found at http://www.clinicaltrials.gov/ by entering the search term “READ-2″.

About Ranibizumab
Ranibizumab is designed to block a natural protein in the body called vascular endothelial growth factor (VEGF), which is produced in excessive amounts in people with diabetes. VEGF causes leakage in the small blood vessels of the eye that can lead to vision loss and blindness. In the Phase 1 clinical trial, Dr. Quan Dong Nguyen, Dr. Peter Campochiaro, Dr. Diana Do, and colleagues at the Wilmer Eye Institute of Johns Hopkins University treated 20 patients with chronic diabetic macular edema with ranibizumab. The trial participants received injections of the drug, with follow-up injections at one, two, four, and six months. The outcome revealed that ranibizumab significantly reduced macular swelling in all patients and improved visual acuity. The Phase 1 clinical trial for DME followed the investigative work by Genentech, Inc., who manufactures ranibizumab. Ranibizumab was approved by the U.S. Food and Drug Administration for the treatment of patients with wet age related macular degeneration in June 2006. 

 

 

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.7 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF’s expenditures directly support research and research-related education.